Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score N/A
- Piotroski Score N/A
- Grade N/A
- Symbol (PBM)
- Company Psyence Biomedical Ltd. Common Shares
- Price $0.19
- Changes Percentage (-18.88%)
- Change -$0.04
- Day Low $0.18
- Day High $0.23
- Year High $14.55
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) N/A
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.00
- Trailing P/E Ratio N/A
- Forward P/E Ratio N/A
- P/E Growth N/A
- Net Income $-51,159,048
Income Statement
Quarterly
Annual
Latest News of PBM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Higher Drug Costs, Less Choice: How PBMs Affect Everyday Americans' Healthcare
The focus is on pharmacy benefit managers (PBMs) facing scrutiny for their role in rising drug costs, anti-competitive practices, and price-fixing. PBMs' opaque operations impact drug availability, co...
By Forbes | 3 weeks ago -
Untangling The $500 Billion PBM Web: The Opaque Relationship Between Employers And Drug Middlemen
The FTC's probe into pharmacy benefit managers for anti-competitive practices has sparked legal actions from state Attorneys General. While PBMs claim to control costs, investigations reveal they stee...
By Forbes | 4 weeks ago -
PBM hearing puts drug pricing in focus
PBM executives are discussing ways to reduce prescription drug prices before Congress. Questions focus on pricing, rebates, and the intermediary role between pharmacies and drug manufacturers. Yahoo F...
By Yahoo! Finance | 1 month ago
